Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.
Barbara Gillespie, MD
Advertisement
Barbara Gillespie, MD, is Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina.
Articles by Barbara Gillespie, MD
Experts outline a 2026 vision for glomerular disease care, including new endpoints, combination therapies, and gene therapy advances.
The PARASOL initiative is reshaping glomerular disease trials through shared data and improved surrogate endpoints.
PLA2R antibodies are advancing precision care in membranous nephropathy and informing new surrogate endpoints through PARASOL.
Anti-nephrin autoantibodies are redefining minimal change disease and enabling more precise, steroid-sparing treatment strategies.
APOL1 kidney disease highlights the need for community trust, increased screening, and stronger clinical trial participation.
Rapid advances in glomerular disease, from single-cell tech to biomarkers and phase 3 trials, are reshaping diagnosis and treatment.
Advertisement
Latest Updated Articles
ISGD and the Fastest 5 Years in Glomerular DiseaseMarch 6th 2026
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
3
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5